Tendencies and research directions on the antidiabetics’ market
April 18, 2010
| Abstract Title: | Tendencies and research directions on the antidiabetics’ market |
| Authors: | Claudiu Morgovan1, Smaranda Cosma2, Steliana Ghibu3, Marius Bota2, Madalina Valeanu4 |
| Affiliation: | 1 Department of Pharmaceutical Marketing and Legislation, Faculty of Medicine, Pharmacy and Dentistry, „Vasile Goldiş” Western University of Arad, Romania 2 Department of Marketing, Faculty of Business, „Babeş Bolyai” University, Cluj-Napoca, Romania 3 Department of Pharmacology, Faculty of Pharmacy, „Iuliu Haţieganu” Medicine and Pharmacy University, Cluj-Napoca, Romania 4 Department of Informatics, Faculty of Medecine, „Iuliu Haţieganu” Medicine and Pharmacy University, Cluj-Napoca, Romania |
| Abstract text: | Introduction: Diabetes mellitus is a pathology with multiple and severe implications. Its prevalence has been continuously increasing during the last years, as well as the number of drugs introduced in its therapy. The value of the antidiabetics global market was evaluated at over 18 billion USD in 2005. The following five international producers hold the biggest share: NovoNordisk, Takeda, Sanofi-Aventis, GlaxoSmithkline and Eli Lilly. Results and discussions: The two bestselling drugs in the USA in 2008 were Actos and Lantus, two products of latest generation, which, however, seems to be a global tendency. As far as the OAD (Oral Antidiabetic Drug) category is concerned, the products to be prescribed in the following years will be those of latest generation, such as thiazolidinedione, GLP-1 analogues, DPP-4 inhibitors, as well as their fixed combinations with metformine. Rapid or slow acting Insulin analogues and their combinations with isophane insulins replace the classic insulin drugs which seem to be outdated. Conclusions: The USA holds 50% of the global market of diabetes significantly influencing this market on a global level. Innovative molecules, whose sales are expanding on the American market (Actos, Lantus, Januvia, Byetta etc.) will replace the already existing ones. The diabetes market will be marked by the going off patent of some molecules with representative turnovers as well as by the introduction of new molecules, especially from the class of GLP-1 analogues or DPP-4 inhibitors or of new insulin drugs with non-parenteral administration for which several researches are currently on the roll. |
| Keywords: | diabetes mellitus, prescriptions, tendencies, brand |
| Presentation type: | Poster |
| Correspondence: | no. 1 Feleacului St., Arad, Romania |
| Email: | claudiumorgovan@yahoo.com |
About The Author
